書籍詳細

I. 化学療法の最近の進歩

P.8 掲載の参考文献

• 1) 成田善孝: 脳・神経・脊髄イラストレイテッド 病態生理とアセスメント 脳腫瘍1) 神経膠腫(神経上皮性腫瘍). ナーシング 29(5): 58-61, 2009.

• 2) 成田善孝: 転移性脳腫瘍 転移性脳腫瘍に対する化学療法. 日本臨牀 68(10S): 593-597, 2010.

• 3) 成田善孝: 転移性脳腫瘍治療の問題点と手術適応. 脳神外ジャーナル 16(11): 820-827, 2007.

• 4) 成田善孝: 専門医に求められる最新の知識 脳腫瘍 脳腫瘍に対する抗腫瘍薬の基礎. 脳神外速報 16(7): 642-648, 2006.

• 5) 成田善孝: 抗悪性腫瘍薬 Temozolomide. 腫瘍内科 4(3): 280-287, 2009.

• 6) Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996, 2005.
  pubmed

• 7) Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10): 997-1003, 2005.
  pubmed

• 8) Okita Y, Narita Y, Miyakita Y, et al: Reactivation of cytomegalovirus following treatment of malignant glioma with temozolomide. lnt Canc Conf J 1(1): 53-57, 2012.

• 9) Ohno M, Narita Y, Miyakita Y, et al: Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide-case report. Neurol Med Chir (Tokyo) 51(10): 728-731, 2011.
  pubmed

• 10) 成田善孝, 澤村 豊, 小林浩之・他: 再発悪性神経膠腫に対するベバシズマブ単独投与試験(第II相臨床試験). 日脳神外科会抄集 2011J-0671, 2011.

• 11) van Breemen MS, Wilms EB and Vecht CJ: Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. LancetNeurol 6(5): 421-430, 2007.
  pubmed

P.16 掲載の参考文献

• 1) Sutow WW, Gehan EA, Vietti TJ, et al: Multidrug chemotherapy in pulmonary treatment of osteosarcoma.J Bone Joint Surg Am 58(5): 629-633, 1976.
  pubmed

• 2) Rosen G, Murphy ML, Huvos AG, et al: Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37(1): 1-11, 1976.
  pubmed

• 3) Luce JK, Thurman WG, Isaacs BL, et al: Clinical trials with the antitumor agent 5- (3,3-dimethyl-1-triazeno) imidazole-4-carboxamide(NSC45388). Cancer Chemother Rep 54 (2): 119-124, 1970.

• 4) O'Bryan RM, Luce JK, Talley RW, et al: Phase II evaluation of adriamycin in human neoplasia. Cancer 32(1): 1-8, 1973.

• 5) Yap BS, Baker LH, Sinkovics JG, et al: Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64(1): 93-98, 1980.
  pubmed

• 6) Iwamoto Y, Tanaka K, Isu K, et al: Multiinstitutional phase H study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci 14(4): 397-404, 2009.

• 7) Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348(8): 694-701, 2003.

• 8) Elias A, Ryan L, Sulkes A, et al: Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Onco 7(9): 1208-1216, 1989.
  pubmed

• 9) Bay JO, Ray-Coquard I, Fayette J, et al: Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: aretrospective analysis. Int J Cancer 119(3): 706-711, 2006.

• 10) Frustaci S, Gherlinzoni F, De Paoli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Onco 19(5): 1238-1247, 2001.

II. 多様化する化学療法を理解する(1) <肺癌>

P.23 掲載の参考文献

• 1) Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2): 85-91, 2002.
  pubmed

• 2) Okamoto H, Watanabe K, Kunikane H, et al: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97(2): 162-169, 2007.
  pubmed

• 3) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311(7010):899-909, 1995.

• 4) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer. a systematic review and meta analysis of individual patient data from 16 randomized Controlled trials. J Clin Oncol 26(28): 4617-4625, 2008.
  pubmed

• 5) Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin versus carboplatin based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer lnst 99(11): 847-857, 2007.

• 6) Scagliotti GV, Parikh P, von Pawel J, et al Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21): 3543-3551, 2008.
  pubmed

• 7) Okamoto I, Yoshioka H, Morita S, et al: Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28 (36): 5240-5246, 2010.

• 8) Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550,2006.
  pubmed

• 9) Ranpura V, Hapani S and Wu S: Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5): 487-494, 2011.

• 10) Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10) : 947-957, 2009

III. ランチョンセミナー

P.29 掲載の参考文献

• 1) Mehrabian A and Ksionzky S: Factors of interpersonal behavior and judgment in social groups. Psychol Rep 28(2): 4834-4892, 1971.

• 2) Fujimori M, Akechi T, Morita T, et al: Preferences of cancer patients regarding the disclosure of bad news. Psychooncology 16(6): 573-581, 2007.
  pubmed

• 3) Takayama T, Yamazaki Y and Katsumata N: Relationship between outpatients' perceptions of physicians' communication styles and patients' anxiety levels in a Japanese oncology setting. Soc Sci Med 53(10): 1335-1350, 2001.

• 4) Baile WF, Buckman R, Leuzi R, et al: SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist 5(4): 302-311, 2000.

• 5) Finset A, Ekeberg O, Eide H, et al: Long term benefits of communication skills training for cancer doctors. Psychooncology 12(7): 686-693, 2003.
  pubmed

• 6) http://jpos-society.org/activities/cst.php

IV. 多様化する化学療法を理解する(2) <胃癌>

P.35 掲載の参考文献

• 1) Aiba K: Upper gastrointestinal tumors. Cancer Chemotherapy and Biological Response Modifiers, Annual 19 (edited by Giaccone G, Schilsky R and Sondel P), Elsevier Science, Amsterdam, 2001, pp535-545.

• 2) MacDonald JS, Woolley PV, Smythe T, et al: 5-fluorouracil, adriamycin, and mitomycin-C (FAM)combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44(1): 42-47, 1979.
  pubmed

• 3) Wils JA, Klein HO, Wagener DJ, et al: Sequential high-dose methotrexate and flourouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9(5): 827-831, 1991.

• 4) Wilke H, Preusser P, Fink U, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7(9): 1318-1326, 1989.
  pubmed

• 5) Preusser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7(9): 1310-1317, 1989.
  pubmed

• 6) Cocconi G, Bella M, Zironi S, et al: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12(12): 2687-2693, 1994.

• 7) Wilke H, Preusser P, Stahl M, et al: Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 29(1): 83-84, 1991.
  pubmed

• 8) Ychou M, Astre C, Rouanet P, et al: A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur J Callcer 32A(11): 1933-1937, 1996.

• 9) Kelsen D, Atiq OT, Saltz L, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10(4): 541-548, 1994.

• 10) Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18(14): 2648-2657, 2000.

• 11) Cocconi G, Carlini P, Gamboni A, et al: Italian Oncology Group for Clinical Research (GOIRC). PELF is More Active than FAMTX in Metastatic Gastric Carcinoma (MGC). Proc Am Soc Clin Oncol 20: 126a, #501, 2001.

• 12) Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15(1): 261-267, 1997.

• 13) Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10(11): 1063-1069, 2009.
  pubmed

• 14) Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9 (3): 215-221, 2008.

• 15) Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9): 1547-1553, 2010.
  pubmed

• 16) Fujii M, Kim YH, Satoh T, et al: Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial update. J Clin Oncol 29(15 suppl): abstr 4016, 2011.

• 17) Narahara H, Iishi H, Imamura H, et al: Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GCO301/TOP-002). Gastric Cancer 14(1): 72-80, 2011.

• 18) Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30): 3968-3976, 2011.
  pubmed

• 19) Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697, 2010.
  pubmed

V. 多様化する化学療法を理解する(3) <乳癌>

P.50 掲載の参考文献

• 1) Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8): 1736-1747, 2011.
  pubmed

• 2) 黒井克昌: 乳がん. がん診療パーフェクト (佐々木常雄/編), 羊土社, 東京, 2010, pp231-245.

• 3) 黒井克昌: Her2陽性乳癌に対する分子標的療法. 乳癌-基礎と臨床の最新研究動向-, 日本臨牀社, 東京, 2012. (印刷中)

• 4) 戸井雅和/編著: 乳癌レビュー2012. メディカルレビュー社, 大阪, 2011.

• 5) 日本乳癌学会/編: 乳癌診療ガイドライン疫学・診断編2011年版. 金原出版, 東京, 2011.

• 6) 日本乳癌学会/編: 乳癌診療ガイドライン治療編2011年版. 金原出版, 東京, 2011.

• 7) Kuroi K, Yamashita T, Aruga T, et al: Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer: a case report. J Med Case Reports 5: 495, 2011.

• 8) Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339(14): 974-984, 1998.
  pubmed

• 9) 金澤麻衣子, 黒井克昌: 乳がん case2: 皮膚潰瘍を伴う進行乳がん. がん診療パーフェクト(佐々木常雄/編著), 羊土社, 東京, 2010, pp358-359.

• 10) 黒井克昌, 戸井雅和: 男性乳癌. 癌と化学療法 30(5): 599-605, 2003.
  Medical*Online